Omeros Hires Nadia Dac as Chief Commercial Officer
January 26 2021 - 07:45AM
Business Wire
Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac
has joined Omeros as its Chief Commercial Officer. In this role,
Ms. Dac will be responsible for all commercial operations at
Omeros, including overseeing preparations for the commercial launch
of narsoplimab, the company’s mannan-binding lectin-associated
serine protease-2 (MASP-2) inhibitor. A Biologics License
Application for narsoplimab in the treatment of hematopoietic stem
cell transplant-associated thrombotic microangiopathy is under
Priority Review by U.S. Food and Drug Administration. Ms. Dac will
also be responsible for driving continued sales growth of Omeros’
commercial product OMIDRIA® (phenylephrine and ketorolac
intraocular solution 1%/0.3%), the only drug of its kind approved
for use during cataract and lens replacement surgery.
“We’re pleased that Nadia has joined our senior leadership
team,” said Gregory A. Demopulos, M.D., chairman and chief
executive officer of Omeros. “Nadia has already hit the ground
running, and her high-caliber expertise is a welcome and timely
addition at this important juncture in our company’s development.
The breadth and depth of her U.S. and global commercial experience
as a strategic leader will be a valuable asset to Omeros as we look
ahead to bringing our second product to market and advancing our
diverse pipeline.”
With deep expertise spanning all commercial functions including
marketing, market access and promotion, sales, pipeline management,
business development and partnerships, Ms. Dac brings almost three
decades of international experience building teams and launching
products as a strategic commercial leader at large and small
biopharmaceutical companies. She joins Omeros from her most recent
role as the chief commercial officer at Alder Pharmaceuticals where
she built the commercial team to launch Vyepti® in the migraine
prevention market, which later was acquired by Lundbeck. Before
joining Alder, she served as vice president of global specialty
commercial development at AbbVie where she led the therapeutic area
and business development strategies for neuroscience, virology,
hepatology, renal, cystic fibrosis and women's health. Prior to
AbbVie, Nadia held several roles of increasing responsibility at
Novartis, building the commercial organization that successfully
launched Gilenya® and Extavia®. Before Novartis, Nadia led
marketing for Biogen’s multiple sclerosis products Tysabri® and
Avonex® and for Pfizer’s Alzheimer's product Aricept®. She also
spent several years in positions of increasing responsibility at
Johnson & Johnson and Eli Lilly where she started her career in
marketing and sales.
“I am excited to be part of the strong leadership team at
Omeros,” said Ms. Dac. “With the restoration of reimbursement for
OMIDRIA, the expected launch of narsoplimab and the impressive and
cutting edge assets in our pipeline, the opportunities for
commercial success are tremendous. I look forward to leading
Omeros’ commercial efforts to capitalize on those
opportunities.”
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting inflammation, complement-mediated diseases, disorders of
the central nervous system and immune-related diseases, including
cancers. Its commercial product OMIDRIA (phenylephrine and
ketorolac intraocular solution) 1%/0.3% continues to gain market
share in cataract surgery. Omeros’ lead MASP-2 inhibitor
narsoplimab targets the lectin pathway of complement and is the
subject of a rolling biologics license application under priority
review by FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Narsoplimab is
also in multiple late-stage clinical development programs focused
on other complement-mediated disorders, including IgA nephropathy,
atypical hemolytic uremic syndrome and COVID-19. Omeros’ MASP-3
inhibitor OMS906, which targets the complement system’s alternative
pathway, recently entered the clinic, and the company’s PDE7
inhibitor OMS527 has successfully completed its Phase 1 trial.
Omeros’ pipeline holds a diverse group of preclinical programs
including a novel antibody-generating technology and a proprietary
GPCR platform through which it controls 54 new GPCR drug targets
and their corresponding compounds. One of these novel targets,
GPR174, modulates a new cancer immunity axis recently discovered by
Omeros, and the company is advancing small-molecule GPR174
inhibitors. For more information about Omeros and its programs,
visit www.omeros.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which are
subject to the “safe harbor” created by those sections for such
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “can,” “could,” “estimate,”
“expect,” “goal,” “intend,” “likely”, “look forward to,” “may,” “on
track,” “plan,” “potential,” “predict,” “project,” “prospects,”
“scheduled,” “should,” “slated,” “targeting,” “will,” “would” and
similar expressions and variations thereof. Forward-looking
statements, including statements regarding anticipated regulatory
submissions, the timing and results of ongoing or anticipated
clinical trials, and the therapeutic application of Omeros’
investigational product, are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. Omeros’ actual results could differ
materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, risks
associated with product commercialization and commercial
operations, unproven preclinical and clinical development
activities, financial condition and results of operations,
regulatory oversight, intellectual property claims, competitive
developments, litigation, and the risks, uncertainties and other
factors described under the heading “Risk Factors” in the company’s
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC) on March 2, 2020, as supplemented by our Quarterly
Reports on Form 10-Q filed with the SEC and subsequent filings with
the SEC. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking
statements, and the company assumes no obligation to update these
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210126005473/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701 jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Feb 2024 to Mar 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2023 to Mar 2024